Image

    Spironolactone and Breast Cancer: Fear Not!

    Warren R. Heymann
    Studysummary This analysis found that spironolactone use is not associated with an increased risk of breast cancer recurrence in female survivors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Spironolactone Use Does Not Increase the Risk of Female Breast Cancer Recurrence: A Retrospective Analysis Journal of The American Academy of Dermatology · 2020
    2. Safety of 5α-Reductase Inhibitors and Spironolactone in Breast Cancer Patients Receiving Endocrine Therapies Breast Cancer Research and Treatment · 2018
    3. Female Pattern Hair Loss: A Clinical, Pathophysiologic, and Therapeutic Review International Journal of Women's Dermatology · 2018

    Related research 3

    1. Spironolactone for the Treatment of Acne: A 4-Year Retrospective Study Dermatology · 2017
    2. Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss Journal of The American Academy of Dermatology · 1999
    3. Lack of Effect of Spironolactone on Hair Shaft Diameter in Hirsute Females Postgraduate medical journal · 1989